DermTech (NASDAQ:DMTK – Get Free Report)‘s stock had its “hold” rating restated by investment analysts at Lake Street Capital in a research report issued on Friday, Benzinga reports. They currently have a $0.63 price target on the stock. Lake Street Capital’s target price suggests a potential downside of 2.17% from the stock’s previous close. A […]
DermTech (NASDAQ:DMTK – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Stephens in a research note issued on Friday, Benzinga reports. They presently have a $1.50 price objective on the stock. Stephens’ price target points to a potential upside of 132.92% from the company’s previous close. Separately, BTIG Research […]
DermTech, Inc. (NASDAQ:DMTK – Get Free Report) fell 0.9% on Tuesday . The company traded as low as $0.60 and last traded at $0.61. 48,834 shares were traded during mid-day trading, a decline of 85% from the average session volume of 321,284 shares. The stock had previously closed at $0.62. Analyst Upgrades and Downgrades Separately, […]
DermTech (NASDAQ:DMTK – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, February 29th. Analysts expect DermTech to post earnings of ($0.54) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. DermTech Stock […]
DermTech (NASDAQ:DMTK – Get Free Report) and BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Profitability This table compares DermTech and BioNexus […]